S. D'Aloisio

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

M. Gleave, A. Tolcher, K. Chi, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

706 POSTER A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies

K. Gelmon, S. Chia, C. Kollmannsberger, 2007 .

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

M. Gleave, A. Tolcher, C. Takimoto, 2005, Clinical Cancer Research.

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

E. Eisenhauer, K. Gelmon, M. Moore, 2003, Investigational New Drugs.

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

E. Eisenhauer, K. Gelmon, A. Tolcher, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.